Ryan Ahmed1, Claire Ryan1, Seth Christman1, Damian Elson1, Camilo Bermudez1, Bennett A Landman1, Sarah M Szymkowicz1, Brian D Boyd1, Hakmook Kang1, Warren D Taylor2. 1. School of Medicine (RA), Vanderbilt University, Nashville, TN; Department of Psychiatry and Behavioral Sciences (SC, DE, BAL, SMS, BDB, WDT), Vanderbilt University Medical Center, Nashville, TN; Department of Biomedical Engineering (CB, BAL), Vanderbilt University, Nashville TN; Department of Electrical Engineering and Computer Science (BAL), Vanderbilt University, Nashville, TN; Department of Biostatistics (HK), Vanderbilt University Medical Center, Nashville, TN; Geriatric Research, Education, and Clinical Center (WDT), Veterans Affairs Tennessee Valley Health System, Nashville, TN. 2. School of Medicine (RA), Vanderbilt University, Nashville, TN; Department of Psychiatry and Behavioral Sciences (SC, DE, BAL, SMS, BDB, WDT), Vanderbilt University Medical Center, Nashville, TN; Department of Biomedical Engineering (CB, BAL), Vanderbilt University, Nashville TN; Department of Electrical Engineering and Computer Science (BAL), Vanderbilt University, Nashville, TN; Department of Biostatistics (HK), Vanderbilt University Medical Center, Nashville, TN; Geriatric Research, Education, and Clinical Center (WDT), Veterans Affairs Tennessee Valley Health System, Nashville, TN. Electronic address: warren.d.taylor@vanderbilt.edu.
Abstract
OBJECTIVE: Late-life depression (LLD) is characterized by accelerated biological aging. Accelerated brain aging, estimated from structural magnetic resonance imaging (sMRI) data by a machine learning algorithm, is associated with LLD diagnosis, poorer cognitive performance, and disability. We hypothesized that accelerated brain aging moderates the antidepressant response. DESIGN AND INTERVENTIONS: Following MRI, participants entered an 8-week randomized, controlled trial of escitalopram. Nonremitting participants then entered an open-label 8-week trial of bupropion. PARTICIPANTS: Ninety-five individuals with LLD. MEASUREMENTS: A machine learning algorithm estimated each participant's brain age from sMRI data. This was used to calculate the brain-age gap (BAG), or how estimated age differed from chronological age. Secondary sMRI measures of aging pathology included white matter hyperintensity (WMH) volumes and hippocampal volumes. Mixed models examined the relationship between sMRI measures and change in depression severity. Initial analyses tested for a moderating effect of MRI measures on change in depression severity with escitalopram. Subsequent analyses tested for the effect of MRI measures on change in depression severity over time across trials. RESULTS: In the blinded initial phase, BAG was not significantly associated with a differential response to escitalopram over time. BAG was also not associated with a change in depression severity over time across both arms in the blinded phase or in the subsequent open-label bupropion phase. We similarly did not observe effects of WMH volume or hippocampal volume on change in depression severity over time. CONCLUSION: sMRI markers of accelerated brain aging were not associated with treatment response in this sequential antidepressant trial. Published by Elsevier Inc.
OBJECTIVE: Late-life depression (LLD) is characterized by accelerated biological aging. Accelerated brain aging, estimated from structural magnetic resonance imaging (sMRI) data by a machine learning algorithm, is associated with LLD diagnosis, poorer cognitive performance, and disability. We hypothesized that accelerated brain aging moderates the antidepressant response. DESIGN AND INTERVENTIONS: Following MRI, participants entered an 8-week randomized, controlled trial of escitalopram. Nonremitting participants then entered an open-label 8-week trial of bupropion. PARTICIPANTS: Ninety-five individuals with LLD. MEASUREMENTS: A machine learning algorithm estimated each participant's brain age from sMRI data. This was used to calculate the brain-age gap (BAG), or how estimated age differed from chronological age. Secondary sMRI measures of aging pathology included white matter hyperintensity (WMH) volumes and hippocampal volumes. Mixed models examined the relationship between sMRI measures and change in depression severity. Initial analyses tested for a moderating effect of MRI measures on change in depression severity with escitalopram. Subsequent analyses tested for the effect of MRI measures on change in depression severity over time across trials. RESULTS: In the blinded initial phase, BAG was not significantly associated with a differential response to escitalopram over time. BAG was also not associated with a change in depression severity over time across both arms in the blinded phase or in the subsequent open-label bupropion phase. We similarly did not observe effects of WMH volume or hippocampal volume on change in depression severity over time. CONCLUSION: sMRI markers of accelerated brain aging were not associated with treatment response in this sequential antidepressant trial. Published by Elsevier Inc.
Authors: Bruce Fischl; David H Salat; André J W van der Kouwe; Nikos Makris; Florent Ségonne; Brian T Quinn; Anders M Dale Journal: Neuroimage Date: 2004 Impact factor: 6.556
Authors: Sabrina M Darrow; Josine E Verhoeven; Dóra Révész; Daniel Lindqvist; Brenda W J H Penninx; Kevin L Delucchi; Owen M Wolkowitz; Carol A Mathews Journal: Psychosom Med Date: 2016-09 Impact factor: 4.312
Authors: Stephen Salloway; Patricia A Boyle; Stephen Correia; Paul F Malloy; Deborah A Cahn-Weiner; Lon Schneider; K Ranga Rama Krishnan; Raj Nakra Journal: Am J Geriatr Psychiatry Date: 2002 Jan-Feb Impact factor: 4.105
Authors: D C Steffens; C E Byrum; D R McQuoid; D L Greenberg; M E Payne; T F Blitchington; J R MacFall; K R Krishnan Journal: Biol Psychiatry Date: 2000-08-15 Impact factor: 13.382
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Warren D Taylor; Douglas R McQuoid; Martha E Payne; Anthony S Zannas; James R MacFall; David C Steffens Journal: Am J Geriatr Psychiatry Date: 2013-11-22 Impact factor: 4.105